$27.50
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Apnimed Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2026-07-31. Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The firm's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Key stats
Open
$25.81
Volume
350.45K
Market cap
$1.06B
Prev. close
$25.56
Impl / hst vl
-
Open interest
$0.00
$25.66
Day’s Range
$27.96
$16.12
52W Range
$35.29
Valuation
Analysts estimates
Avg. price target
$51.34
The top 5 analysts forecasts that 12-month price may increase by 86.69%, with a low of $41.41 and a high of $63.00
$41.41
Low
$51.34
Avg
$63.00
High
Current price
Earnings
Revenue
Net income
Previous EPS
-Estimate EPS
-$0.52
Actual EPS
Estimate EPS
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply